An allosteric inhibitor of Bcr-Abl (IC50 0.121 UM) inhibits the Bcr-Abl mutants Bcr-AblG250E Bcr-AblE255V and Bcr-AblM351T (IC50s 4.52 0.38 and 0.93 UM respectively) reduces viral titers in IBV-infected Vero cells at 10 UM increases survival in a recalcitrant mutant Bcr-AblT315I mouse bone marrow transplantation model at 75 mg/kg